Evolus (NASDAQ:EOLS) Trading Down 6.5% - Here's Why

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price dropped 6.5% during trading on Monday . The stock traded as low as $13.06 and last traded at $13.06. Approximately 548,849 shares traded hands during trading, a decline of 41% from the average daily volume of 922,538 shares. The stock had previously closed at $13.97.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EOLS. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Tuesday, January 21st. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, January 22nd. Finally, Barclays boosted their target price on Evolus from $20.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, January 27th.

Evolus Stock Down 2.2 %

The stock's fifty day moving average price is $11.97 and its 200 day moving average price is $13.91. The stock has a market cap of $830.13 million, a P/E ratio of -14.41 and a beta of 1.33. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Institutional Investors Weigh In On Evolus

Hedge funds have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Evolus in the fourth quarter worth approximately $49,000. IFP Advisors Inc lifted its holdings in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Evolus in the 3rd quarter valued at $132,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock valued at $148,000 after acquiring an additional 1,291 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Evolus during the third quarter worth about $191,000. Institutional investors own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.